Armetheon, Inc., is a privately held San Francisco Bay area based clinical stage biopharmaceutical company focused on the development of novel drugs for highly unmet need. The company was founded by three successful biotech entrepreneurs and pharmaceutical executives with several years of drug R&D and company building experience.

 

Core development program:

 Tecarfarin
(ATI-5923)

Potentially best-in-class, late clinical trial stage, novel safe and effective orally active anti-coagulant. It is a potent inhibitor of VKOR that is not metabolized by CYP2C9 enzyme and, hence, has a superior profile to warfarin. Unlike, non-monitored oral anti-coagulant drugs that are direct inhibitors of thrombin or Factor Xa, tecarfarin can be used in patients with (i) prosthetic heart valves, and/or (ii) who have renal dysfunction.

   

Non-Core development programs:

Naronapride
(ATI-7505)

Potentially best-in-class, late clinical trial stage, novel safe and effective orally active 5HT4 agonist for gastrointestinal (GI) disorders. These include upper GI (such as sGERD, PPI-resistant GERD, gastroparesis) and lower GI (such as chronic constipation) disorders.

Budiodarone
(ATI-2042)

Potentially best-in-class, mid-clinical trial stage, novel safe and effective anti-arrhythmic agent (both oral and intravenous) for the treatment of patients with atrial fibrillation.

Research programs:

A program to study potential new uses for our drug candidates in clinical development in particular for new orphan indications and a program to identify novel antibiotics targeting drug-resistant bacteria.